⏳ Final hours! Save up to 60% OFF InvestingProCLAIM SALE

Labcorp executive sells $2.8 million in stock

Published 12/04/2024, 11:02 PM
LH
-

Glenn A. Eisenberg, Executive Vice President at Labcorp Holdings Inc. (NYSE:LH), a $19.86 billion healthcare services provider, recently executed a series of stock transactions involving the company's common stock. On December 2, Eisenberg sold 11,711 shares at an average price of $240.43, resulting in a total transaction value of approximately $2.8 million. According to InvestingPro data, the stock is currently trading near its 52-week high of $247.99, suggesting strong market confidence.

Additionally, Eisenberg acquired shares through the exercise of stock options. He acquired 8,923 shares at a price of $209.25 per share and 2,788 shares at a price of $221.67 per share, totaling approximately $2.5 million. Following these transactions, Eisenberg's direct ownership in Labcorp amounts to 31,289 shares.

These transactions were reported in a recent SEC filing.

In other recent news, Laboratory Corporation of America (NYSE:LH), also known as LabCorp, has seen some significant developments. Baird recently revised LabCorp's price target, reducing it to $286.00 from $289.00, but maintained an Outperform rating on the company's stock. This adjustment comes despite LabCorp's disappointing Early Development results since the second quarter of 2022. However, LabCorp anticipates modest year-over-year growth in the fourth quarter, driven by an improving trend expected to continue into 2025.

In the company's third-quarter earnings call for 2024, LabCorp reported a 7% year-over-year revenue increase to $3.3 billion. The diagnostics revenue grew by 9%, and biopharma laboratory services rose by 3%. Adjusted earnings per share (EPS) were up by 4% at $3.50. The company also highlighted strategic acquisitions and the launch of new products, contributing to its positive outlook.

These recent developments indicate LabCorp's resilience in the face of challenges and its commitment to growth. The company's focus on improving its laboratory capabilities and integration of new acquisitions suggests a positive trajectory for the future.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.